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Joachim Schofer, MDkABSTRACTOBJECTIVES The aim of this study was to assess the 1-year outcome after transcatheter aortic valve replacement
(TAVR) of the Direct Flow Medical (DFM) valve in patients with severe symptomatic aortic stenosis who were
contraindicated or high risk for surgery.
BACKGROUND The DFM transcatheter heart valve is a new-generation, nonmetallic aortic valve with a pressurized
support structure and conformable double-ring annular sealing delivered through an 18-F sheath. The device allows
repositioning, retrieval, and assessment of valve performance before permanent implantation.
METHODS A prospective multicenter European registry was set up to determine the safety and performance of
the valve in 100 consecutive patients (10 centers). Echocardiographic and angiographic data were evaluated by an
independent core laboratory, and adverse events were adjudicated by a clinical events committee using Valve Academic
Research Consortium criteria.
RESULTS Patients were 83.1  5.9 years of age and had a logistic EuroSCORE of 22.5  11.3% and a Society of
Thoracic Surgeons score of 9.7  8.7%. Correct valve positioning was obtained in 99% of cases with a combined
30-day safety endpoint at 10%, including major stroke in 5.0%, major vascular complications in 2.0%, and death
in 1%. At 12 months, 95% of patients were in New York Heart Association functional class I or II. Freedom from any
death was 90%, and freedom from any death or major stroke was 85%. Echocardiography demonstrated none/trace to
mild aortic regurgitation in 100% of patients and an unchanged mean aortic gradient of 12.2  6.6 mm Hg and
effective oriﬁce area of 1.6  0.4 cm2.
CONCLUSIONS At 1 year, the DFM transcatheter heart valve had durable hemodynamics. This study demon-
strates that the low rate of early complications and the low risk of signiﬁcant aortic regurgitation translated into
midterm clinical beneﬁt. (J Am Coll Cardiol Intv 2016;9:68–75) © 2016 by the American College of Cardiology
Foundation.
AB BR E V I A T I O N S
AND ACRONYM S
DFM = Direct Flow Medical
VARC = Valve Academic
Research Consortium
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 1 , 2 0 1 6 Lefèvre et al.
J A N U A R Y 1 1 , 2 0 1 6 : 6 8 – 7 5 Discover Trial: Direct Flow 1-Year Outcomes
69T ranscatheter aortic valve replacement hasbeen used to successfully treat high-risk pa-tients with symptomatic aortic stenosis
(1,2). The ability to fully reposition or remove the
valve after deployment avoids potential misplace-
ment that can result in coronary obstruction, mitral
valve injury, severe aortic regurgitation, and valve
embolization (3,4).
The Direct Flow Medical (DFM) transcatheter aortic
valve system has a nonmetallic design with a pres-
surized support structure that allows precise posi-
tioning, retrieval, and assessment of valve
performance before ﬁnal release. The DFM valve is
delivered through a ﬂexible, 18-F sheath, which en-
sures excellent trackability and minimizes vascular
complications. The 18-F sheath is used for all valve
sizes.SEE PAGE 76The DISCOVER (Evaluation of the Direct Flow
Medical Percutaneous Aortic Valve 18F System for the
Treatment of Patients with Severe Aortic Stenosis)
study is a prospective, nonrandomized, multicenter
European study to evaluate the early and long-term
performance of the DFM valve in an extreme-risk
patient population. Early safety and efﬁcacy of this
technology have been previously reported (5). Most
notably, the device minimized the occurrence of
moderate/severe aortic regurgitation. As aortic re-
gurgitation may negatively affect prognosis, the DFM
technology may be expected to improve long-term
outcomes. Here, we report the 12-month outcomes
of the DISCOVER study to address mainly 2 questions.
First, is the reduction in aortic regurgitation stable at
midterm? Second, is the reduction in occurrence of
moderate/severe aortic regurgitation associated with
improved survival?From the *Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier,
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Patients who were older than 70 years of age
with symptomatic severe aortic valve steno-
sis were evaluated for enrollment. All pa-
tients were required to have a logistic
EuroSCORE of $20% or other high surgical risk fea-
tures with agreement for transcatheter aortic valve
replacement by both the cardiologist and cardiotho-
racic surgeon at the clinical site. Inclusion and
exclusion criteria were reviewed by an independent
patient review committee and were previously re-
ported (5). Echocardiographic and angiographic im-
ages were evaluated by an independent core
laboratory (MedStar, Washington, DC). Aortic regur-
gitation was assessed by Valve Academic Research
Consortium (VARC) II criteria (6).
The primary endpoint was freedom from all-cause
mortality at 30 days. Secondary endpoints included
VARC II–deﬁned patient safety and device success (6).
Clinical events and study safety were adjudicated by
an independent committee (Online Appendix 1). All
operators were trained on a simulated bench model
and in an animal laboratory before the ﬁrst attempted
implantation. The study was designed with a pre-
planned roll-in training cohort of 3 patients per site.
These patients were also included in the current
analysis.
DEVICE DESCRIPTION. The DFM valve is a nonme-
tallic percutaneous bovine pericardial valve (Figure 1)
with an expandable Dacron polyester double-ring
design that encircles and captures the native valve
annulus. This technology ensures anchoring of the
bioprosthesis and minimizes potential paravalvular
leakage. A complete description of the valve and im-
plantation technique was previously published (5,7).Massy, France; ySan Raffaele Hospital, Milan, Italy;
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FIGURE 1 The Direct Flow Medical Percutaneous Aortic Valve
The Direct Flow Medical valve prosthesis consists of bovine
pericardial leaﬂets and an inﬂatable nonmetallic scaffold,
allowing the valve to be repositioned and retrieved if necessary.
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70The bioprosthesis used in the study was provided in a
25-mm size for annular diameters of 19 to 24 mm and
a 27-mm size for annular diameters of 22 to 26 mm.
Valve sizing recommendations were based on
computed tomography dimensions and perimeter-
derived diameters in particular. The valvuloplasty
balloon that was selected had a diameter 2 to 3 mm
smaller than the valve size but never exceeding the
annulus diameter. Patients with a coronary artery
height <15 mm were treated using a valve size
smaller than the aortic bulbus to allow adequate
perfusion and access to coronary arteries. During
the course of the study, DFM received the CE mark
for the 29-mm valve to accommodate those
patients with native annulus diameters between
26 and 28 mm.
STATISTICS. Summary statistics are provided for
baseline characteristics and all outcome variables.
No hypothesis testing was performed. Percentages
and counts are provided for categorical data and
mean  SD, and ranges for continuous data. Time-
to-event endpoints (e.g., survival analyses) were
analyzed using the Kaplan-Meier method. To ensure
the appropriateness of pooling the results across
clinical sites in this small study of 100 patients,
an analysis of variance was performed across the
9 centers.RESULTS
PATIENT POPULATION. A total of 100 patients with
severe symptomatic aortic stenosis were enrolled at
9 clinical sites in 4 European countries (Online
Appendix). The baseline demographics have been
described previously (5) and are illustrated and
compared with those of the CoreValve (Medtronic,
Minneapolis, Minnesota) high-risk pivotal study (8)
and the PARTNER (Placement of AoRTic TraNs-
cathetER Valve Trial Edwards SAPIEN Transcatheter
Heart Valve) high-risk randomized study (1) in
Table 1.
In summary, the mean age of the patients was
83.1  5.9 years, and 50% were female. The mean
gradient was 45.8  9.7 mm Hg, and the effective
oriﬁce area was 0.65  0.17 cm2. The logistic
EuroSCORE was 22.5  11.3%, and the Society of
Thoracic Surgeons score was 9.7  8.7%. The mean
left ventricular ejection fraction was 56.7  8.9%;
58% of the patients had coronary artery disease,
23% had previous coronary artery bypass surgery,
27% had chronic renal insufﬁciency, and 13% had
severe COPD.30-DAY OUTCOMES. The 30-day outcome was
described previously (5) and is illustrated in Table 2.
In summary, correct valve positioning was obtained
in 99% of patients and device success in 91%. The
combined 30-day safety endpoint was observed in
10%, including major stroke in 5.0%, major vascular
complication in 2.0%, and death in 1.0%. A new
pacemaker was implanted in 17.0% of patients.
12-MONTH OUTCOMES. One-year clinical follow-up
was obtained in all patients. The main results are
described in Table 2 and compared with those of
the CoreValve high-risk pivotal study (8) and the
PARTNER high-risk randomized study (1). Figure 2
demonstrates the clinical outcomes observed at
1 year. Overall survival was 90%, cardiovascular sur-
vival was 93%, and freedom from death and major
stroke was 85% at 1 year.
At 1 year, 96% of patients were in New York Heart
Association functional class I or II (Figure 3). No
patient was in New York Heart Association func-
tional class IV. Hospitalizations for valve-related
symptoms of heart failure occurred in 9.4% pa-
tients between 31 and 182 days post-procedure and
8.7% of patients between 6 and 12 months. There
were no cases of valve dysfunction (endocarditis,
thrombosis, migration, or embolization). There was
1 repeat procedure due to a low implantation
TABLE 1 Baseline Characteristics and Echocardiographic Findings of the Patients in the Direct
Flow Medical Study and Comparison With the PARTNER B and CoreValve Pivotal Study
DISCOVER
(N ¼ 100)
CoreValve HR*
(N ¼ 394)
PARTNER HR*
(N ¼ 348)
Age, yrs 83.1  5.9 83.2  7.1 83.6  6.8
Male 50/100 (50.0) 211/394 (46.4) 201/348 (57.8)
STS score 9.7  8.7 7.3  3.0 11.8  3.3
Logistic EuroSCORE 22.5  11.3 17.6  13.0 29.3  16.5
NYHA functional class
II 38/100 (38.0) 56/394 (14.2) 20/348 (5.7)
III or IV 58/100 (58.0) 338/394 (85.8) 328/3,487 (94.3)
Previous atrial ﬁbrillation or atrial ﬂutter 30/100 (30.0) 161/393 (41.0) 80/196 (40.8)
Coronary artery disease 57/98 (58.2) 297/394 (75.4) 260/347 (74.9)
Previous myocardial infarction 9/100 (9.0) 101/394 (25.6) 92/343 (26.8)
Previous intervention
CABG 23/100 (23.0) 117/394 (29.7) 147/345 (42.6)
PCI 31/99 (31.3) 133/394 (33.8) 116/341 (34.0)
Cerebrovascular disease 5/99 (5.1)† 101/394 (25.6) 95/324 (29.3)
Peripheral vascular disease 23/98 (23.5) 163/391 (41.7) 148/344 (43.0)
COPD 13/100 (13.0) 52/390 (13.3) 151/348 (43.4)
Chronic kidney disease (stage 4/5) 27/100 (27.0)‡ 48/387 (12.4) 38/343 (11.1)
Permanent pacemaker 13/100 (13.0) 92/394 (23.4) 69/345 (20.0)
Extensive calciﬁed aorta 6/100 (6.0) 24/394 (4.9) 2/348 (0.6)
Echocardiographic ﬁndings
Aortic valve area, cm2 0.7  0.2 0.7  0.2 0.7  0.2
Mean aortic valve gradient, mm Hg 45.8  9.7 47.3  14.6 42.7  14.6
Mean LVEF 56.7  8.9 54.5  14.4 52.5  13.5
Moderate or severe mitral regurgitation§ 5/85 (5.9) ND 66/344 (19.8)
Values are mean  SD or n/N (%). *CoreValve HR is the CoreValve high-risk pivotal trial (8); PARTNER HR is the
PARTNER high-risk patients (1). †Previous carotid or cerebrovascular intervention. ‡Chronic kindney disease not
limited to stage 4/5. §Moderate or severe mitral regurgitation was deﬁned as regurgitation of grade 3þ or higher.
CABG ¼ coronary artery bypass grafting; COPD ¼ chronic obstructive pulmonary disease; LVEF ¼ left ven-
tricular ejection fraction; ND ¼ no data; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary
intervention; STS ¼ Society of Thoracic Surgeons.
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71of the valve. The patient underwent successful sur-
gical aortic valve replacement during the index
hospitalization.
The rate of permanent pacemaker implantation
between 30 days and 12 months was 4.0%.
CAUSES OF DEATH. From inclusion to 12-month
follow-up, 10 deaths were recorded. Causes of death
during the course of the study are summarized in
Table 3. They were mainly noncardiovascular, with
2 cases of sudden death, 1 of unknown cause, and
1 cerebral hemorrhage.
ECHOCARDIOGRAPHIC HEMODYNAMICS. Patients un-
derwent core laboratory evaluation of echocardio-
grams and experienced a signiﬁcant and persistent
reduction in transvalvular gradients. Because
some echocardiographic data were missing, a paired
analysis was also performed. The mean gradient
decreased from 45.8  9.7 mm Hg at baseline to 12.6 
5.8 mm Hg at 30 days and remained stable at
12 months with a mean gradient of 12.2  6.6 mm Hg
(Figure 4). The effective oriﬁce area (Figure 5)
at baseline was 0.65  0.17 cm2, increased to 1.50 
0.48 cm2 at 30 days, and was stable at 12 months
(1.57  0.42 cm2).
AORTIC REGURGITATION. The severity of central and
paravalvular aortic regurgitation was graded as none
or mild in all patients with evaluable echocardio-
graphic assessment at 12 months using both VARC-1
and American College of Cardiology/American HeartTABLE 2 Clinical Outcome at 1 Month and 1 Year in the DFM Study and Comparison With PARTNER High-Risk Patients and CoreValve High-Risk Pivotal Study*
Outcome
DISCOVER
(N ¼ 100)
CoreValve HR
(N ¼ 390)
PARTNER HR
(N ¼ 348)
1 Month 1 Year 1 Month 1 Year 1 Month 1 Year
Death
From any cause 1 (1.0) 10 (10.0) 13 (3.3) 55 (14.2) 12 (3.4) 84 (24.2)
From a cardiac cause 1 (1.0) 7 (7.0) ND ND 11 (3.2) 47 (14.3)
Any stroke 7 (7.0) 10 (10.0) 19 (4.9) 34 (8.8) 16 (4.7) 20 (6.0)
Minor stroke 2 (2.0) 2 (2.0) 4 (1.0) 11 (3.0) 3 (0.9) 3 (0.9)
Major stroke 5 (5.0) 8 (8.0) 15 (3.9) 23 (5.8) 13 (3.8) 17 (5.1)
Death or major stroke 5 (5.0) 15 (15.0) 23 (5.9) 64 (16.3) 24 (6.9) 92 (26.5)
Myocardial infarction 1 (1.0) 2 (2.0) ND ND 0 1 (0.4)
Any vascular complication 13 (13.0) 14 (14.0) ND ND 59 (17.0) 62 (18.0)
Major vascular complication 2 (2.0) 3 (3.0) 23 (5.9) 24 (6.2) 38 (11.0) 39 (11.3)
Acute kidney injury 1 (1.0)‡ 3 (3.0)‡ 23 (6.0) 23 (6.0) 4 (1.2) 12 (3.9)
Major bleeding 9 (9.0) 10 (10.0) 109 (28.1) 114 (29.5) 32 (9.3) 49 (14.7)
Endocarditis 0 0 ND ND 0 2 (0.6)
New-onset atrial ﬁbrillation 11 (11.0) 13 (13.0) 45 (11.7) 60 (15.9) 30 (8.6) 42 (12.1)
New pacemaker 17 (17.0) 21 (21.0) 76 (19.8) 85 (22.3) 13 (3.8) 19 (5.7)
Values are n (%) or mean  SD. *CoreValve HR is the CoreValve high-risk pivotal trial (8); PARTNER HR is the PARTNER high-risk patients (1). ‡Includes acute kidney injury stage 3 only.
ND ¼ no data.
FIGURE 2 Kaplan-Meier Estimates of Freedom From Mortality and/or Mayor Stroke Through 1 Year
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72Association criteria. Speciﬁcally, paravalvular aortic
regurgitation was none or trace in 84% of patients at
30 days and 79% at 12 months. Total aortic regur-
gitation was none or trace in 68% and mild or lessFIGURE 3 New York Heart Association Functional Class
New York Heart Association functional class at baseline and
12-month follow-up.in 100% of patients at 12 months (Figures 6 and 7).
A ﬁgure with paired echocardiographic data obtained
at 30 days and 1 year follow-up can be found in the
Online Figure 1.
DISCUSSION
The study demonstrates excellent 1-year clinical
outcomes with the DFM transcatheter valve systemTABLE 3 Cause of Death in the DISCOVER Study
No. of Days Post-procedure Cause of Death
12 Pneumonia
112 Sudden death
115 Gastrointestinal bleed
164 Sudden death
213 Unknown cause
238 Multiple organ failure
266 Cerebral hemorrhage
284 Chronic obstructive pulmonary disease
331 Cancer
334 Vascular dementia
FIGURE 5 Effective Oriﬁce Area
Evolution of effective oriﬁce aortic area (cm2) at baseline and follow-up
(global and paired data).
FIGURE 4 Transvalvular Aortic Mean Pressure Gradient
Evolution of transvalvular aortic mean pressure gradient (mm Hg) at baseline and
follow-up (global and paired data).
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73in high- and extreme-risk patients. This is the ﬁrst
prospective multicenter trial evaluating second-
generation transcatheter aortic valve replacement
technology and demonstrating near elimination of
paravalvular aortic regurgitation. This was a signiﬁ-
cant limitation with ﬁrst-generation technology that
resulted in worse survival rates in patients with more
than mild AR (9).
The DFM valve has a conformable ring design
that minimizes aortic regurgitation. At 1 year, 100%
of patients had mild or less aortic regurgitation,
and 68.2% had none or trace. This is in contrast to
the results obtained with balloon-expandable and
self-expanding devices, for which the reported
incidence of moderate to severe AR ranged from
6% to 27%, respectively (9–13). The most recent
data from the PARTNER trial comparing the
SAPIEN with the SAPIEN XT valve (Edwards Life-
sciences, Irvine, California) demonstrated a 20.9%
and 29.2% incidence of moderate or severe AR at
1 year (12). The ability to reposition the valve
assists in minimizing the risk of paravalvular
regurgitation.
The all-cause mortality rate at 12 months
after DFM implantation was 10%. These results
compare favorably with the most recent multi-
center prospective, nonrandomized CoreValve trial
in extreme-risk patients (13) that demonstrated a 1-
year mortality rate of 24% in the extreme-risk
group. The logistic EuroSCORE was similar in both
studies: 22.5% versus 22.6%. This study also re-
ported a combined death and major stroke rate of
26% versus the DISCOVER trial rate of 15% at 12
months. The PARTNER 2B trial of extreme-risk pa-
tients reported a 23.7% and 22.5% mortality rate at
12 months in the SAPIEN and SAPIEN XT cohorts,
respectively (12).
Valvular hemodynamics were well maintained
at 1 year. Both the transvalvular gradient and
effective oriﬁce area were maintained from the
post-procedure evaluation out to 1 year. This
demonstrates that, owing to its design and the
polymerization of the rings, the frame maintains
its radial strength and anatomic position. This is
consistent with results from a previous prototype
version of this valve that was durable at 5-year
follow-up (14).
The current study reﬂects the outcomes from the
ﬁrst 100 patients ever treated with the current
iteration of this valve and delivery system. The
operators had no previous experience with the
current system, and only 1 physician (J.S.) had
experience with the ﬁrst-generation prototype de-
vice (14). The total procedure time was 91  47 minfor the ﬁrst 25 patients and decreased with experi-
ence to 72  21 min for the last 25 implants
(Figure 8). This demonstrates that despite the
unique technology and deployment technique (7) of
a nonmetallic frame, this device has an acceptably
short learning curve.
FIGURE 8 Evolution of Procedure Time in Date Order
FIGURE 6 Total Aortic Regurgitation
Total aortic regurgitation post-procedure and at follow-up by the core laboratory.
FIGURE 7 Paravalvular Aortic Regurgitation
Paravalvular aortic regurgitation post-procedure and at follow-up by the core laboratory.
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74The ability to reposition and evaluate the ﬁnal
result before implantation yielded several important
safety advantages. These are highlighted by the fact
that there was no case of aortic rupture, valve
embolization, or coronary occlusion.
STUDY LIMITATIONS. The main limitation of this
study is the relatively small cohort and the fact
that it is not a randomized trial that compares
the results with those of the ﬁrst-generation devices.
Additional real-world registry outcomes are ongoing
in Europe and the pivotal U.S. randomized study
SALUS (TranScatheter Aortic Valve RepLacement
System Pivotal Trial The Safety and Effectiveness
of the Direct Flow Medical Tanscatheter Aortic
Valve System) has already started. This study
will include 912 extreme surgical risk patients
who will be randomized 2:1 with the Medtronic
CoreValve. Echocardiographic images were either
unavailable or of insufﬁcient quality for all patients
to enable analysis by the core laboratory, and
this could be a limitation for echocardiographic
analysis.CONCLUSIONS
The low rate of early complications, the low risk of
signiﬁcant aortic regurgitation, and stable hemody-
namics at 1 year after implantation of the DFM valve
translated into midterm beneﬁt with a low mortality
rate of 10% in high-risk patients.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Thierry Lefèvre, Institut Cardiovasculaire Paris Sud,
Hôpital Privé Jacques Cartier, 6 avenue du Noyer
Lambert, 91300 Massy, France. E-mail: t.lefevre@
icps.com.fr.PERSPECTIVES
WHAT IS KNOWN? Paravalvular leak remains a
signiﬁcant issue after percutaneous aortic valve
implantation.
WHAT IS NEW? These preliminary data show that
the risk of paravalvular leak is decreased with the DFM
valve, which is a conformable and repositionable
percutaneous aortic valve.
WHAT IS NEXT? A pivotal U.S. study is ongoing (the
SALUS study).
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